KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Clover Health Investments (CLOV) EBITDA Margin (2020 - 2025)

Clover Health Investments' EBITDA Margin history spans 6 years, with the latest figure at 10.1% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 323.0% year-over-year to 10.1%; the TTM value through Dec 2025 reached 4.35%, down 130.0%, while the annual FY2025 figure was 4.34%, 126.0% down from the prior year.
  • EBITDA Margin reached 10.1% in Q4 2025 per CLOV's latest filing, down from 4.85% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2.16% in Q2 2024 to a low of 93.78% in Q4 2021.
  • Average EBITDA Margin over 5 years is 19.03%, with a median of 9.67% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: tumbled -7990bps in 2021, then skyrocketed 6453bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 93.78% in 2021, then surged by 67bps to 30.65% in 2022, then increased by 27bps to 22.36% in 2023, then skyrocketed by 69bps to 6.87% in 2024, then crashed by -47bps to 10.1% in 2025.
  • Per Business Quant, the three most recent readings for CLOV's EBITDA Margin are 10.1% (Q4 2025), 4.85% (Q3 2025), and 2.16% (Q2 2025).